-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66

Benzinga·11/03/2026 13:00:50
Listen to the news
Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.